About CNS Pharmaceuticals
CNS Pharmaceuticals is a company based in Houston (United States) founded in 2017. CNS Pharmaceuticals has raised $22.53 million across 1 funding round. The company has 5 employees as of December 31, 2024. CNS Pharmaceuticals offers products and services including Berubicin and TPI 287.
- Headquarter Houston, United States
- Employees 5 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cns Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$14.86 M (USD)21.18as on Dec 31, 2024
-
EBITDA
-$14.9 M (USD)21.01as on Dec 31, 2024
-
Total Equity Funding
$22.53 M (USD)
in 1 rounds
-
Latest Funding Round
$22.53 M (USD), Series B
May 04, 2026
-
Investors
Not available
-
Employee Count
5
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of CNS Pharmaceuticals
CNS Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol CNSP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of CNS Pharmaceuticals
CNS Pharmaceuticals offers a comprehensive portfolio of products and services, including Berubicin and TPI 287.
First anthracycline to cross blood-brain barrier for glioblastoma treatment.
Novel taxane permeable to blood-brain barrier for brain malignancies.
Funding Insights of CNS Pharmaceuticals
CNS Pharmaceuticals has successfully raised a total of $22.53M through 1 strategic funding round. The most recent funding activity was a Series B round of $22.53 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by CNS Pharmaceuticals
Investment portfolio details for CNS Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CNS Pharmaceuticals
Detailed financials for CNS Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cns Pharmaceuticals Comparisons
Peer comparison for CNS Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CNS Pharmaceuticals
Detailed competitors of CNS Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cns Pharmaceuticals
Complete news archive for CNS Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CNS Pharmaceuticals
CNS Pharmaceuticals was founded in 2017 and raised its 1st funding round 9 years after it was founded.
CNS Pharmaceuticals is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
John Climaco is the current CEO of CNS Pharmaceuticals.
CNS Pharmaceuticals is a funded company, having raised a total of $22.53M across 1 funding round to date.
As of Dec 31, 2024, the latest employee count at CNS Pharmaceuticals is 5.
CNS Pharmaceuticals was founded in 2017 in Houston, United States, focusing on the oncology sector. A pipeline of anti-cancer drug candidates is maintained, including berubicin, which crosses the blood-brain barrier to target tumor cells, and TPI 287, aimed at glioblastoma multiforme. Efforts are directed toward primary and metastatic cancers in the brain and central nervous system, with operations centered on drug development for these indications.
CNS Pharmaceuticals offers Berubicin and TPI 287.
Yes, CNS Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol CNSP.
The ticker symbol of CNS Pharmaceuticals is CNSP on NASDAQ.